The connection between driver mutations and efficacy of immune-checkpoint inhibitors (ICIs) is the focus of intense investigations. In lung adenocarcinoma (LUAD), KEAP1/STK11 alterations have been tied to immunoresistance. Nevertheless, the heterogeneity characterizing immunotherapy efficacy suggests the contribution of still unappreciated events.
KEAP1 and TP53 frame genomic, evolutionary and immunological subtypes of lung adenocarcinoma with different sensitivity to immunotherapy / Scalera, Stefano; Mazzotta, Marco; Corleone, Giacomo; Sperati, Francesca; Terrenato, Irene; Krasniqi, Eriseld; Pizzuti, Laura; Barba, Maddalena; Vici, Patrizia; Gallo, Enzo; Buglioni, Simonetta; Visca, Paolo; Pescarmona, Edoardo; Marinelli, Daniele; De Nicola, Francesca; Ciuffreda, Ludovica; Goeman, Frauke; Fanciulli, Maurizio; Giusti, Raffaele; Vecchione, Andrea; De Maria, Ruggero; Cappuzzo, Federico; Marchetti, Paolo; Ciliberto, Gennaro; Maugeri-Saccà, Marcello. - In: JOURNAL OF THORACIC ONCOLOGY. - ISSN 1556-0864. - 16:12(2021), pp. 2065-2077. [10.1016/j.jtho.2021.08.010]
KEAP1 and TP53 frame genomic, evolutionary and immunological subtypes of lung adenocarcinoma with different sensitivity to immunotherapy
Mazzotta, MarcoCo-primo
;Pizzuti, Laura;Barba, Maddalena;Gallo, Enzo;Visca, Paolo;Pescarmona, Edoardo;Marinelli, Daniele;Fanciulli, Maurizio;Giusti, Raffaele;Vecchione, Andrea;De Maria, Ruggero;Marchetti, Paolo;
2021
Abstract
The connection between driver mutations and efficacy of immune-checkpoint inhibitors (ICIs) is the focus of intense investigations. In lung adenocarcinoma (LUAD), KEAP1/STK11 alterations have been tied to immunoresistance. Nevertheless, the heterogeneity characterizing immunotherapy efficacy suggests the contribution of still unappreciated events.| File | Dimensione | Formato | |
|---|---|---|---|
|
Scalera_KEAP1_2021.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
3.57 MB
Formato
Adobe PDF
|
3.57 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
